As this is associated with higher costs and risks for the patients (e.g., general anesthesia, contrast agents), a prospective study is needed to define a new follow-up schedule in NR2F6-overexpressing HNSCC. Here, NR2F6 is linked to head and neck squamous cell carcinoma.